Therapeutic Drug Monitoring

Information

Monoclonal antibody biologics are often used as therapeutic agents. These biologics act as selective inhibitors of relevant target structure and have the potential to influence the natural course of progressive diseases, such as inflammatory bowel disease (IBD).

Therapeutic drug monitoring (TDM) is the quantitative measure of drug levels in the blood to maximize efficacy and safety at different timepoints.^1,2 TDM has been shown to be effective in reducing the costs of patient treatment and management.¹

Reduction in a drug level could indicate that anti-drug antibodies (ADA) are being produced against the drug. These endogenous antibodies complex the drug, leading to early elimination from the body and/or inhibit the mechanism of action.

References

1. Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, Kamperidis N, Kobayashi T, Kotze PG, Lambert J, Noor NM, Roblin X, Roda G, Vande Casteele N, Yarur AJ, Arebi N, Danese S, Paul S, Sandborn WJ, Vermeire S, Cheifetz AS, Peyrin-Biroulet L; International Consortium for Therapeutic Drug Monitoring. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):171-185. doi: 10.1016/S2468-1253(21)00223-5. PMID: 35026171; PMCID: PMC10187071.
2. Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology. 2017 Sep;153(3):827-834. doi: 10.1053/j.gastro.2017.07.032. Epub 2017 Aug 3. PMID: 28780013.

Therapeutic Drug Monitoring products

For in vitro diagnostic use. Rx Only.
These products are not manufactured by EUROIMMUN. Visit www.procisedx.com or contact your local EUROIMMUN representative for more information.